Literature DB >> 9243037

Early discharge of low-risk febrile neutropenic children and adolescents with cancer.

V M Aquino1, I Tkaczewski, G R Buchanan.   

Abstract

During the past decade, a relatively lower-risk patient population of febrile neutropenic children with cancer (over one-half of all these patients) has been identified. These patients can be safely discharged from the hospital before their absolute neutrophil count (ANC) exceeds 500/mm3. To evaluate the practice of early discharge of these patients, 580 consecutive episodes of chemotherapy-induced febrile neutropenia in 253 children and adolescents with cancer between June 1992 and May 1995 were reviewed. Three hundred thirty episodes ended in discharge before the patient's ANC was > 500/mm3. Patients were characterized as being at relatively lower risk if they had sterile blood cultures, were afebrile for > 24 hours, appeared well, and were thought to have evidence of marrow recovery. Of the 330 episodes, only 21 (6%) were associated with admission for recurrent fever during the subsequent 7 days. In retrospect, in only six of these 21 cases of readmission (or 2% of 330 episodes) was there evidence of bone marrow recovery, and none of the blood cultures were positive during the subsequent hospitalization. All patients who met low-risk criteria fared well during their second hospitalization. This early discharge strategy was safe and resulted in substantial cost savings.

Entities:  

Mesh:

Year:  1997        PMID: 9243037     DOI: 10.1086/514512

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

2.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 3.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Mark Holdsworth; Jeff Hanrahan; Bernadette Albanese; Jami Frost
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Repeating blood cultures in neutropenic children with persistent fevers when the initial blood culture is negative.

Authors:  Jeremy Rosenblum; Juan Lin; Mimi Kim; Adam S Levy
Journal:  Pediatr Blood Cancer       Date:  2012-10-09       Impact factor: 3.167

5.  Approach to febrile neutropenia in the general paediatric setting.

Authors:  Lillian Sung; Donna L Johnston
Journal:  Paediatr Child Health       Date:  2007-01       Impact factor: 2.253

6.  Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards.

Authors:  Sasmita Biswal; Chaitali Godnaik
Journal:  Ecancermedicalscience       Date:  2013-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.